RESUMO
BACKGROUND: Medullary thyroid cancer (MTC) is a rare cancer that has historically been managed by endocrinologists. In 2011, the first of several multi- targeted tyrosine kinase inhibitors was approved as treatment for MTC. These drugs have changed the management of MTC to teams that include oncologists and oncology nurses. OBJECTIVES: This article illustrates MTC diagnostics, surveillance, management of adverse drug reactions, and disease progression through a case study. METHODS: An overview of MTC is offered, followed by an in-depth case study that examines MTC from the patient's perspective. FINDINGS: Oncology nurses can influence patient outcomes through the provision of patient education, support, and management of disease and treatment complications.
Assuntos
Carcinoma Neuroendócrino/tratamento farmacológico , Carcinoma Neuroendócrino/cirurgia , Enfermagem Oncológica/normas , Guias de Prática Clínica como Assunto , Inibidores de Proteínas Quinases/uso terapêutico , Neoplasias da Glândula Tireoide/tratamento farmacológico , Neoplasias da Glândula Tireoide/cirurgia , Adulto , Carcinoma Neuroendócrino/enfermagem , Carcinoma Neuroendócrino/fisiopatologia , Feminino , Humanos , Doenças Raras/diagnóstico , Doenças Raras/tratamento farmacológico , Doenças Raras/cirurgia , Neoplasias da Glândula Tireoide/enfermagem , Neoplasias da Glândula Tireoide/fisiopatologia , Resultado do TratamentoRESUMO
Since I was diagnosed with a neuroendocrine tumour in June 2011, my upper gastrointestinal specialist nurse Eleanor Church has been a pillar of support. She is so cheerful, warm, kind and compassionate that I actually look forward to my oncology appointments at Bedford Hospital.
Assuntos
Atitude do Pessoal de Saúde , Carcinoma Neuroendócrino/enfermagem , Relações Enfermeiro-Paciente , Recursos Humanos de Enfermagem Hospitalar/psicologia , Satisfação do Paciente , Pacientes/psicologia , Humanos , Reino UnidoRESUMO
Neuroendocrine tumors (NETs) are rare, generally indolent tumors that are lethal in the metastatic setting. Treatment options to control tumor growth are limited. In clinical trials, investigational oral mammalian target of rapamycin (mTOR) inhibitors have shown activity in patients with metastatic NETs. The purpose of this article is to provide oncology nurses with a background on the mechanism of action of mTOR inhibitors in the setting of NETs. Increased understanding of the role of mTOR in the pathogenesis of NETs has led to the study of mTOR inhibitor investigational agents in NETs. Treatments are evolving and currently focusing on targeted agents such as mTOR inhibitors. Understanding the mechanisms of action of targeted agents is a critical component of nursing knowledge.